You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBortezomib
Accession NumberDB00188  (APRD00828, DB07475)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells. Bortezomib is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
Structure
Thumb
Synonyms
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
External Identifiers
  • LDP 341
  • LDP-341
  • LDP341
  • PS 341
  • PS-341
  • PS341
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Bortezomibpowder for solution3.5 mgintravenous; subcutaneousActavis Pharma Company2015-11-17Not applicableCanada
Bortezomibpowder for solution3.5 mgintravenous; subcutaneousApotex IncNot applicableNot applicableCanada
Bortezomib for Injectionpowder for solution3.5 mgintravenous; subcutaneousDr Reddys Laboratories LtdNot applicableNot applicableCanada
Bortezomib for Injectionpowder for solution3.5 mgintravenous; subcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Bortezomib for Injectionpowder for solution3.5 mgintravenous; subcutaneousTeva Canada Limited2015-01-06Not applicableCanada
VelcadePowder for solution for injection3.5 mgIntravenous use Subcutaneous useJanssen Cilag International Nv2004-04-26Not applicableEu
Velcadeinjection, powder, lyophilized, for solution3.5 mg/1intravenous; subcutaneousMillennium Pharmaceuticals, Inc.2003-05-13Not applicableUs
VelcadePowder for solution for injection1.0 mgIntravenous useJanssen Cilag International Nv2004-04-26Not applicableEu
Velcadepowder for solution3.5 mgintravenous; subcutaneousJanssen Inc2005-02-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bortezomib Accordpowder for solution for injection3.5 mgIntravenous use, Subcutaneous useAccord Healthcare Ltd2015-07-20Not applicableEu
Bortezomib HospiraPowder for solution for injection3.5 mgIntravenous use, Subcutaneous useHospira Uk Limited2016-07-22Not applicableEu
Bortezomib SunPowder for solution for injection3.5 mgIntravenous use, Subcutaneous useSun Pharmaceutical Industries (Europe) B.V.2016-07-22Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII69G8BD63PP
CAS number179324-69-7
WeightAverage: 384.237
Monoisotopic: 384.196885774
Chemical FormulaC19H25BN4O4
InChI KeyGXJABQQUPOEUTA-RDJZCZTQSA-N
InChI
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
IUPAC Name
[(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid
SMILES
CC(C)C[[email protected]](NC(=O)[[email protected]](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids and derivatives
Alternative Parents
Substituents
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Amphetamine or derivatives
  • Pyrazinecarboxamide
  • Pyrazine carboxylic acid or derivatives
  • Fatty acyl
  • Benzenoid
  • Pyrazine
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Boronic acid
  • Boronic acid derivative
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organic metalloid salt
  • Organooxygen compound
  • Organonitrogen compound
  • Organoboron compound
  • Organic metalloid moeity
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
PharmacodynamicsBortezomib is a drug that inhibits the mammalian 26S proteasome. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma. Tumor cells, that is, rapidly dividing cells, appear to be more sensitive to proteasome inhibition.
Mechanism of actionBortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortezomib is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis. In addition, bortezomib appears to increase the sensitivity of cancer cells to traditional anticancer agents (e.g., gemcitabine, cisplatin, paclitaxel, irinotecan, and radiation).
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding83% over the concentration range of 100-1000 ng/ml.
Metabolism

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2, while bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form 2 deboronated metabolites that subsequently undergo hydroxylation to several metabolites which are inactive as 26S proteasome inhibitors.

SubstrateEnzymesProduct
Bortezomib
Bortezomib metabolite M1Details
Bortezomib
Bortezomib metabolite M2Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M3Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M3Details
Bortezomib metabolite M3
Not Available
Bortezomib metabolite M4Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M5Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M6Details
Bortezomib metabolite M2
Bortezomib metabolite M8Details
Bortezomib metabolite M8
Not Available
Bortezomib metabolite M33Details
Bortezomib
Not Available
Bortezomib metabolite M34Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M25Details
Bortezomib metabolite M1
Not Available
Bortezomib metabolite M26Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M27Details
Bortezomib metabolite M2
Not Available
Bortezomib metabolite M28Details
Bortezomib
Bortezomib metabolite M23 or M24 (1)Details
Bortezomib
Bortezomib metabolite M23 or M24 (2)Details
Route of eliminationThe pathways of elimination of bortezomib have not been characterized in humans.
Half lifeThe mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.
Clearance
  • 102 L/h [patients with multiple myeloma following the first dose for doses of 1 mg/m2]
  • 112 L/h [patients with multiple myeloma following the first dose for doses of 1.3 mg/m2]
  • 15 – 32 L/h [patients with multiple myeloma following subsequent doses for doses of 1 and 1.3 mg/m2]
ToxicityCardiovascular safety pharmacology studies in monkeys show that lethal IV doses are associated with decreases in blood pressure, increases in heart rate, increases in contractility, and ultimately terminal hypotension. In monkeys, doses of 3.0 mg/m2 and greater (approximately twice the recommended clinical dose) resulted in progressive hypotension starting at 1 hour and progressing to death by 12 to 14 hours following drug administration.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6935
Blood Brain Barrier-0.6533
Caco-2 permeable-0.6576
P-glycoprotein substrateSubstrate0.5909
P-glycoprotein inhibitor INon-inhibitor0.785
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9445
CYP450 2C9 substrateNon-substrate0.7145
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5209
CYP450 1A2 substrateNon-inhibitor0.855
CYP450 2C9 inhibitorNon-inhibitor0.8267
CYP450 2D6 inhibitorNon-inhibitor0.9304
CYP450 2C19 inhibitorNon-inhibitor0.8108
CYP450 3A4 inhibitorNon-inhibitor0.7308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9604
Ames testNon AMES toxic0.7439
CarcinogenicityNon-carcinogens0.8064
BiodegradationNot ready biodegradable0.9943
Rat acute toxicity2.4537 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9936
hERG inhibition (predictor II)Non-inhibitor0.8593
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Millennium pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Powder for solution for injectionIntravenous use, Subcutaneous use3.5 mg
Injection, powder, lyophilized, for solutionintravenous; subcutaneous3.5 mg/1
Powder for solutionintravenous; subcutaneous3.5 mg
Powder for solution for injectionIntravenous use1.0 mg
Powder for solution for injectionIntravenous use Subcutaneous use3.5 mg
Prices
Unit descriptionCostUnit
Velcade 3.5 mg vial1590.0USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2203936 No2005-04-122015-10-27Canada
US5780454 Yes1997-11-032017-11-03Us
US6083903 No1994-10-282014-10-28Us
US6713446 Yes2002-07-252022-07-25Us
US6958319 Yes2002-07-252022-07-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityThe solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5.Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0532 mg/mLALOGPS
logP0.89ALOGPS
logP1.53ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.04ChemAxon
pKa (Strongest Basic)-0.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.44 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity99.37 m3·mol-1ChemAxon
Polarizability40.48 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Raghavendracharyulu Venkata Palle, Rajasekhar Kadaboina, Veerendeer Murki, Amarendhar Manda, Nageshwar Gunda, Ramaseshagiri Rao Pulla, Mallesha Hanmanthu, Narasimha Naidu Mopidevi, Suresh Kumar Ramdoss, “BORTEZOMIB AND PROCESS FOR PRODUCING SAME.” U.S. Patent US20100226597, issued September 09, 2010.

US20100226597
General References
  1. Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-11. [PubMed:15199612 ]
  2. Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007 Apr;21(4):838-42. Epub 2007 Feb 1. [PubMed:17268529 ]
  3. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. [PubMed:14695130 ]
  4. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [PubMed:15953001 ]
  5. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [PubMed:10363983 ]
  6. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005 May;2(5):357-62. Epub 2005 Apr 21. [PubMed:15846363 ]
External Links
ATC CodesL01XX32
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (199 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Bortezomib can be increased when it is combined with Abiraterone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Bortezomib.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Bortezomib.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Bortezomib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bortezomib.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Bortezomib.
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Bortezomib.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Bortezomib.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Bortezomib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Bortezomib.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Bortezomib.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Bortezomib.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Bortezomib.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Bortezomib.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Bortezomib.
AlosetronThe metabolism of Alosetron can be decreased when combined with Bortezomib.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Bortezomib.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Bortezomib.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Bortezomib.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Bortezomib.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Bortezomib.
AmiodaroneThe serum concentration of Bortezomib can be increased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Bortezomib.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Bortezomib.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Bortezomib.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Bortezomib.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Bortezomib.
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Bortezomib.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Bortezomib.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Bortezomib.
ApremilastThe metabolism of Apremilast can be decreased when combined with Bortezomib.
AprepitantThe serum concentration of Bortezomib can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Bortezomib.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Bortezomib.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Bortezomib.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Bortezomib.
ArmodafinilThe metabolism of Bortezomib can be decreased when combined with Armodafinil.
Arsenic trioxideBortezomib may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe metabolism of Artemether can be decreased when combined with Bortezomib.
ASA404The metabolism of ASA404 can be decreased when combined with Bortezomib.
AsenapineThe metabolism of Asenapine can be decreased when combined with Bortezomib.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Bortezomib.
AtazanavirThe serum concentration of Bortezomib can be increased when it is combined with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Bortezomib.
AtomoxetineThe metabolism of Bortezomib can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Bortezomib.
AV650The metabolism of AV650 can be decreased when combined with Bortezomib.
AvanafilThe metabolism of Avanafil can be decreased when combined with Bortezomib.
AxitinibThe metabolism of Axitinib can be decreased when combined with Bortezomib.
AzelastineThe metabolism of Azelastine can be decreased when combined with Bortezomib.
AzithromycinBortezomib may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Bortezomib can be decreased when combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Bortezomib.
BedaquilineBortezomib may increase the QTc-prolonging activities of Bedaquiline.
BendamustineThe metabolism of Bendamustine can be decreased when combined with Bortezomib.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Bortezomib.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Bortezomib.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Bortezomib.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Bortezomib.
BevacizumabBevacizumab may increase the cardiotoxic activities of Bortezomib.
BexaroteneThe serum concentration of Bortezomib can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Bortezomib.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Bortezomib.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Bortezomib.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Bortezomib.
BoceprevirThe serum concentration of Bortezomib can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bortezomib can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bortezomib.
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Bortezomib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Bortezomib.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Bortezomib.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Bortezomib.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Bortezomib.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Bortezomib.
BudesonideThe metabolism of Budesonide can be decreased when combined with Bortezomib.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Bortezomib.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Bortezomib.
BupropionThe metabolism of Bupropion can be decreased when combined with Bortezomib.
BuspironeThe metabolism of Buspirone can be decreased when combined with Bortezomib.
BusulfanThe metabolism of Busulfan can be decreased when combined with Bortezomib.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Bortezomib.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bortezomib.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Bortezomib.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Bortezomib.
CaffeineThe metabolism of Caffeine can be decreased when combined with Bortezomib.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Bortezomib.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Bortezomib.
CapecitabineThe metabolism of Bortezomib can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of Bortezomib can be decreased when it is combined with Carbamazepine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Bortezomib.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Bortezomib.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Bortezomib.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Bortezomib.
CarmustineThe metabolism of Carmustine can be decreased when combined with Bortezomib.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Bortezomib.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Bortezomib.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Bortezomib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Bortezomib.
CeritinibThe serum concentration of Bortezomib can be increased when it is combined with Ceritinib.
CeritinibBortezomib may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Bortezomib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Bortezomib.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Bortezomib.
ChloramphenicolThe metabolism of Bortezomib can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Bortezomib.
ChloroquineBortezomib may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Bortezomib can be decreased when combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Bortezomib.
ChlorpromazineBortezomib may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Bortezomib can be decreased when combined with Chlorpromazine.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Bortezomib.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Bortezomib.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Bortezomib.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Bortezomib.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Bortezomib.
CimetidineThe metabolism of Bortezomib can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Bortezomib.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Bortezomib.
CiprofloxacinBortezomib may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Bortezomib.
CitalopramThe metabolism of Citalopram can be decreased when combined with Bortezomib.
ClarithromycinThe serum concentration of Bortezomib can be increased when it is combined with Clarithromycin.
ClarithromycinBortezomib may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Bortezomib can be decreased when combined with Clemastine.
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Bortezomib.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Bortezomib.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Bortezomib.
ClobazamThe metabolism of Clobazam can be decreased when combined with Bortezomib.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Bortezomib.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Bortezomib.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Bortezomib.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Bortezomib.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Bortezomib.
ClonidineThe metabolism of Clonidine can be decreased when combined with Bortezomib.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Bortezomib.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Bortezomib.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Bortezomib.
ClotrimazoleThe metabolism of Bortezomib can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Bortezomib is combined with Clozapine.
ClozapineThe metabolism of Bortezomib can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Bortezomib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bortezomib.
CocaineThe metabolism of Cocaine can be decreased when combined with Bortezomib.
CodeineThe metabolism of Codeine can be decreased when combined with Bortezomib.
ColchicineThe metabolism of Colchicine can be decreased when combined with Bortezomib.
ConivaptanThe serum concentration of Bortezomib can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Bortezomib.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Bortezomib.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Bortezomib.
CrizotinibBortezomib may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Bortezomib can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Bortezomib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Bortezomib.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Bortezomib.
Cyproterone acetateThe serum concentration of Bortezomib can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Bortezomib.
DabrafenibThe serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Bortezomib.
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Bortezomib.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Bortezomib.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Bortezomib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Bortezomib.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Bortezomib.
DapsoneThe metabolism of Dapsone can be decreased when combined with Bortezomib.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Bortezomib.
DarunavirThe serum concentration of Bortezomib can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Bortezomib.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Bortezomib.
DasatinibThe serum concentration of Bortezomib can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Bortezomib.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Bortezomib.
DeferasiroxThe serum concentration of Bortezomib can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Bortezomib.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Bortezomib.
DesipramineThe metabolism of Desipramine can be decreased when combined with Bortezomib.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bortezomib.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Bortezomib.
DexamethasoneThe serum concentration of Bortezomib can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Bortezomib.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Bortezomib.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Bortezomib.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Bortezomib.
DiazepamThe metabolism of Diazepam can be decreased when combined with Bortezomib.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Bortezomib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bortezomib.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Bortezomib.
DigoxinDigoxin may decrease the cardiotoxic activities of Bortezomib.
DigoxinThe metabolism of Digoxin can be decreased when combined with Bortezomib.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Bortezomib.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Bortezomib.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Bortezomib.
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Bortezomib.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Bortezomib.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Bortezomib.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Bortezomib.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Bortezomib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Bortezomib.
DolasetronBortezomib may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bortezomib.
DonepezilThe metabolism of Donepezil can be decreased when combined with Bortezomib.
DopamineThe metabolism of Dopamine can be decreased when combined with Bortezomib.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Bortezomib.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Bortezomib.
DoxepinThe metabolism of Doxepin can be decreased when combined with Bortezomib.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Bortezomib.
DoxycyclineThe metabolism of Bortezomib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Bortezomib.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Bortezomib.
DroperidolBortezomib may increase the QTc-prolonging activities of Droperidol.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Bortezomib.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Bortezomib.
EfavirenzThe serum concentration of Bortezomib can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Bortezomib.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Bortezomib.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Bortezomib.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Bortezomib.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Bortezomib.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Bortezomib.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Bortezomib.
EnzalutamideThe serum concentration of Bortezomib can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Bortezomib.
EpinastineThe metabolism of Epinastine can be decreased when combined with Bortezomib.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Bortezomib.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Bortezomib.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Bortezomib.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Bortezomib.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Bortezomib.
ErythromycinBortezomib may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Bortezomib can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Bortezomib.
Eslicarbazepine acetateThe serum concentration of Bortezomib can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Bortezomib.
EstazolamThe metabolism of Estazolam can be decreased when combined with Bortezomib.
EstradiolThe metabolism of Estradiol can be decreased when combined with Bortezomib.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Bortezomib.
EstramustineThe metabolism of Estramustine can be decreased when combined with Bortezomib.
EstroneThe metabolism of Estrone can be decreased when combined with Bortezomib.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Bortezomib.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Bortezomib.
EthanolThe metabolism of Ethanol can be decreased when combined with Bortezomib.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Bortezomib.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Bortezomib.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Bortezomib.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Bortezomib.
EtoposideThe metabolism of Etoposide can be decreased when combined with Bortezomib.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Bortezomib.
EtravirineThe serum concentration of Bortezomib can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Bortezomib.
EverolimusThe metabolism of Everolimus can be decreased when combined with Bortezomib.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Bortezomib.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Bortezomib.
FamotidineThe metabolism of Famotidine can be decreased when combined with Bortezomib.
FelbamateThe metabolism of Felbamate can be decreased when combined with Bortezomib.
FelodipineThe metabolism of Felodipine can be decreased when combined with Bortezomib.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Bortezomib.
FentanylThe metabolism of Fentanyl can be decreased when combined with Bortezomib.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib.
FinasterideThe metabolism of Finasteride can be decreased when combined with Bortezomib.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Bortezomib.
FlecainideBortezomib may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Bortezomib.
FloxuridineThe metabolism of Bortezomib can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Bortezomib can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Bortezomib.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Bortezomib.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Bortezomib.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Bortezomib.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Bortezomib.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Bortezomib.
FlupentixolBortezomib may increase the QTc-prolonging activities of Flupentixol.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Bortezomib.
FlutamideThe metabolism of Flutamide can be decreased when combined with Bortezomib.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Bortezomib.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Bortezomib.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Bortezomib.
FluvoxamineThe metabolism of Bortezomib can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Bortezomib.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Bortezomib.
FosaprepitantThe serum concentration of Bortezomib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Bortezomib can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Bortezomib.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Bortezomib.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Bortezomib.
Fusidic AcidThe serum concentration of Bortezomib can be increased when it is combined with Fusidic Acid.
Gadobenic acidBortezomib may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Bortezomib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Bortezomib.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Bortezomib.
GemifloxacinBortezomib may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe metabolism of Genistein can be decreased when combined with Bortezomib.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Bortezomib.
GlipizideThe metabolism of Glipizide can be decreased when combined with Bortezomib.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Bortezomib.
GlyburideThe metabolism of Glyburide can be decreased when combined with Bortezomib.
GoserelinBortezomib may increase the QTc-prolonging activities of Goserelin.
GranisetronBortezomib may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Bortezomib.
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Bortezomib.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Bortezomib.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Bortezomib.
HaloperidolBortezomib may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Bortezomib can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Bortezomib.
HesperetinThe metabolism of Hesperetin can be decreased when combined with Bortezomib.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Bortezomib.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Bortezomib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Bortezomib.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Bortezomib.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Bortezomib.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Bortezomib.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Bortezomib.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Bortezomib.
IbutilideBortezomib may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Bortezomib can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Bortezomib resulting in a loss in efficacy.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Bortezomib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Bortezomib.
ImatinibThe metabolism of Bortezomib can be decreased when combined with Imatinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Bortezomib.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Bortezomib.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Bortezomib.
IndapamideThe metabolism of Indapamide can be decreased when combined with Bortezomib.
IndinavirThe serum concentration of Bortezomib can be increased when it is combined with Indinavir.
IndinavirThe metabolism of Indinavir can be decreased when combined with Bortezomib.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Bortezomib.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Bortezomib.
IrbesartanThe metabolism of Bortezomib can be decreased when combined with Irbesartan.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Bortezomib.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Bortezomib.
IsoniazidThe metabolism of Bortezomib can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Bortezomib.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Bortezomib.
IsradipineThe metabolism of Isradipine can be decreased when combined with Bortezomib.
ItraconazoleThe serum concentration of Bortezomib can be increased when it is combined with Itraconazole.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Bortezomib.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Bortezomib.
IvacaftorThe serum concentration of Bortezomib can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Bortezomib.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Bortezomib.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Bortezomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Bortezomib.
KetamineThe metabolism of Ketamine can be decreased when combined with Bortezomib.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Bortezomib.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Bortezomib.
KetoconazoleThe serum concentration of Bortezomib can be increased when it is combined with Ketoconazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Bortezomib.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Bortezomib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Bortezomib.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Bortezomib.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Bortezomib.
LenvatinibBortezomib may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Bortezomib.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Bortezomib.
LeuprolideBortezomib may increase the QTc-prolonging activities of Leuprolide.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Bortezomib.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Bortezomib.
LevofloxacinBortezomib may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Bortezomib.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Bortezomib.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Bortezomib.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Bortezomib.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Bortezomib.
LisurideThe metabolism of Lisuride can be decreased when combined with Bortezomib.
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Bortezomib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Bortezomib.
LoperamideThe metabolism of Loperamide can be decreased when combined with Bortezomib.
LopinavirThe serum concentration of Bortezomib can be increased when it is combined with Lopinavir.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Bortezomib.
LoratadineThe metabolism of Loratadine can be decreased when combined with Bortezomib.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Bortezomib.
LosartanThe metabolism of Losartan can be decreased when combined with Bortezomib.
LovastatinThe metabolism of Lovastatin can be decreased when combined with Bortezomib.
LuliconazoleThe serum concentration of Bortezomib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Bortezomib can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Bortezomib.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Bortezomib.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Bortezomib.
MacitentanThe metabolism of Macitentan can be decreased when combined with Bortezomib.
MalathionThe metabolism of Malathion can be decreased when combined with Bortezomib.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Bortezomib.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Bortezomib.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Bortezomib.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Bortezomib.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Bortezomib.
MelatoninThe metabolism of Melatonin can be decreased when combined with Bortezomib.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Bortezomib.
MenadioneThe metabolism of Menadione can be decreased when combined with Bortezomib.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Bortezomib.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Bortezomib.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bortezomib.
MethadoneBortezomib may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Bortezomib can be decreased when combined with Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Bortezomib.
MethotrimeprazineThe metabolism of Bortezomib can be decreased when combined with Methotrimeprazine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Bortezomib.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Bortezomib.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Bortezomib.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Bortezomib.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Bortezomib.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Bortezomib.
MetoprololThe metabolism of Bortezomib can be decreased when combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Bortezomib.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Bortezomib.
MianserinThe metabolism of Mianserin can be decreased when combined with Bortezomib.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Bortezomib.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Bortezomib.
MidazolamThe metabolism of Midazolam can be decreased when combined with Bortezomib.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Bortezomib.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Bortezomib.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Bortezomib.
MitotaneThe serum concentration of Bortezomib can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Bortezomib.
ModafinilThe serum concentration of Bortezomib can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Bortezomib.
MontelukastThe metabolism of Montelukast can be decreased when combined with Bortezomib.
MorphineThe metabolism of Morphine can be decreased when combined with Bortezomib.
MoxifloxacinBortezomib may increase the QTc-prolonging activities of Moxifloxacin.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Bortezomib.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Bortezomib.
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Bortezomib.
NafcillinThe serum concentration of Bortezomib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bortezomib.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Bortezomib.
NaproxenThe metabolism of Naproxen can be decreased when combined with Bortezomib.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Bortezomib.
NefazodoneThe serum concentration of Bortezomib can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Bortezomib.
NelfinavirThe serum concentration of Bortezomib can be increased when it is combined with Nelfinavir.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Bortezomib.
NetupitantThe serum concentration of Bortezomib can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Bortezomib can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Bortezomib.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Bortezomib.
NicotineThe metabolism of Nicotine can be decreased when combined with Bortezomib.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Bortezomib.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Bortezomib.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Bortezomib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Bortezomib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Bortezomib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bortezomib.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Bortezomib.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Bortezomib.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Bortezomib.
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Bortezomib.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Bortezomib.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Bortezomib.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Bortezomib.
OfloxacinBortezomib may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Bortezomib.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Bortezomib.
OlaparibThe metabolism of Bortezomib can be decreased when combined with Olaparib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Bortezomib.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Bortezomib.
OndansetronBortezomib may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Bortezomib.
OsimertinibThe serum concentration of Bortezomib can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Bortezomib.
OuabainOuabain may decrease the cardiotoxic activities of Bortezomib.
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Bortezomib.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Bortezomib.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Bortezomib.
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Bortezomib.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Bortezomib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Bortezomib.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Bortezomib.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Bortezomib.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bortezomib.
PalbociclibThe serum concentration of Bortezomib can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Bortezomib.
PaliperidoneBortezomib may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Bortezomib.
PanobinostatBortezomib may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Bortezomib can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Bortezomib.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Bortezomib.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Bortezomib.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Bortezomib.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Bortezomib.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Bortezomib.
ParoxetineThe metabolism of Bortezomib can be decreased when combined with Paroxetine.
PazopanibBortezomib may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Bortezomib can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineBortezomib may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe serum concentration of Bortezomib can be decreased when it is combined with Pentobarbital.
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Bortezomib.
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Bortezomib.
PerampanelThe metabolism of Perampanel can be decreased when combined with Bortezomib.
PerflutrenBortezomib may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Bortezomib.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Bortezomib.
PermethrinThe metabolism of Permethrin can be decreased when combined with Bortezomib.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Bortezomib.
PethidineThe metabolism of Pethidine can be decreased when combined with Bortezomib.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Bortezomib.
PhenobarbitalThe serum concentration of Bortezomib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Bortezomib.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Bortezomib.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Bortezomib.
PhenytoinThe serum concentration of Bortezomib can be decreased when it is combined with Phenytoin.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Bortezomib.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Bortezomib.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Bortezomib.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Bortezomib.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Bortezomib.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Bortezomib.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Bortezomib.
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Bortezomib.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Bortezomib.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Bortezomib.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Bortezomib.
PosaconazoleThe serum concentration of Bortezomib can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Bortezomib.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Bortezomib.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Bortezomib.
PrazepamThe metabolism of Prazepam can be decreased when combined with Bortezomib.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Bortezomib.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Bortezomib.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Bortezomib.
PrimaquineBortezomib may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Bortezomib can be decreased when it is combined with Primidone.
PrimidoneThe metabolism of Primidone can be decreased when combined with Bortezomib.
ProcainamideBortezomib may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Bortezomib.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Bortezomib.
ProguanilThe metabolism of Proguanil can be decreased when combined with Bortezomib.
PromazineBortezomib may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Bortezomib can be decreased when combined with Promazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Bortezomib.
PropofolThe metabolism of Propofol can be decreased when combined with Bortezomib.
PropranololThe metabolism of Propranolol can be decreased when combined with Bortezomib.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Bortezomib.
PyrimethamineThe metabolism of Bortezomib can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Bortezomib.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Bortezomib.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Bortezomib.
QuinidineThe metabolism of Quinidine can be decreased when combined with Bortezomib.
QuinineThe metabolism of Quinine can be decreased when combined with Bortezomib.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Bortezomib.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Bortezomib.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Bortezomib.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Bortezomib.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Bortezomib.
RasagilineThe metabolism of Rasagiline can be decreased when combined with Bortezomib.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Bortezomib.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Bortezomib.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Bortezomib.
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Bortezomib.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Bortezomib.
RifabutinThe serum concentration of Bortezomib can be decreased when it is combined with Rifabutin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Bortezomib.
RifampicinThe serum concentration of Bortezomib can be decreased when it is combined with Rifampicin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Bortezomib.
RifapentineThe serum concentration of Bortezomib can be decreased when it is combined with Rifapentine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Bortezomib.
RiluzoleThe metabolism of Riluzole can be decreased when combined with Bortezomib.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Bortezomib.
RiociguatThe metabolism of Riociguat can be decreased when combined with Bortezomib.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Bortezomib.
RitonavirThe serum concentration of Bortezomib can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Bortezomib.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Bortezomib.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Bortezomib.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Bortezomib.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Bortezomib.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Bortezomib.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Bortezomib.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Bortezomib.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Bortezomib.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Bortezomib.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Bortezomib.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Bortezomib.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Bortezomib.
SaquinavirThe serum concentration of Bortezomib can be increased when it is combined with Saquinavir.
SaquinavirBortezomib may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Bortezomib.
SecobarbitalThe metabolism of Bortezomib can be increased when combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Bortezomib.
SelexipagThe metabolism of Selexipag can be decreased when combined with Bortezomib.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Bortezomib.
SertindoleThe metabolism of Sertindole can be decreased when combined with Bortezomib.
SertralineThe metabolism of Sertraline can be decreased when combined with Bortezomib.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Bortezomib.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Bortezomib.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Bortezomib.
SilodosinThe metabolism of Silodosin can be decreased when combined with Bortezomib.
SiltuximabThe serum concentration of Bortezomib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bortezomib can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Bortezomib.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Bortezomib.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Bortezomib.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Bortezomib.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Bortezomib.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Bortezomib.
SotalolBortezomib may increase the QTc-prolonging activities of Sotalol.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Bortezomib.
St. John's WortThe serum concentration of Bortezomib can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Bortezomib can be increased when it is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Bortezomib.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Bortezomib.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Bortezomib.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Bortezomib.
SulfisoxazoleBortezomib may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Bortezomib can be decreased when combined with Sulfisoxazole.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Bortezomib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Bortezomib.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Bortezomib.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Bortezomib.
TacrineThe metabolism of Tacrine can be decreased when combined with Bortezomib.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Bortezomib.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Bortezomib.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Bortezomib.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Bortezomib.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Bortezomib.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Bortezomib.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Bortezomib.
TelaprevirThe serum concentration of Bortezomib can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Bortezomib.
TelavancinBortezomib may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Bortezomib can be increased when it is combined with Telithromycin.
TelithromycinBortezomib may increase the QTc-prolonging activities of Telithromycin.
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Bortezomib.
TemazepamThe metabolism of Temazepam can be decreased when combined with Bortezomib.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Bortezomib.
TeniposideThe metabolism of Teniposide can be decreased when combined with Bortezomib.
TenofovirThe metabolism of Bortezomib can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Bortezomib.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Bortezomib.
TeriflunomideThe serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Bortezomib.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Bortezomib.
TetrabenazineBortezomib may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Bortezomib.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Bortezomib.
TheobromineThe metabolism of Theobromine can be decreased when combined with Bortezomib.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Bortezomib.
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Bortezomib.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Bortezomib.
ThioridazineThe metabolism of Bortezomib can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Bortezomib.
ThiothixeneThe metabolism of Thiothixene can be decreased when combined with Bortezomib.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Bortezomib.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Bortezomib.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Bortezomib.
TimololThe metabolism of Timolol can be decreased when combined with Bortezomib.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Bortezomib.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Bortezomib.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Bortezomib.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Bortezomib.
TocilizumabThe serum concentration of Bortezomib can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Bortezomib.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Bortezomib.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Bortezomib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bortezomib.
TopiramateThe metabolism of Bortezomib can be decreased when combined with Topiramate.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Bortezomib.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Bortezomib.
TramadolThe metabolism of Tramadol can be decreased when combined with Bortezomib.
TranylcypromineThe metabolism of Bortezomib can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bortezomib.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Bortezomib.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Bortezomib.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Bortezomib.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Bortezomib.
TriamtereneThe metabolism of Triamterene can be decreased when combined with Bortezomib.
TriazolamThe metabolism of Triazolam can be decreased when combined with Bortezomib.
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Bortezomib.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Bortezomib.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Bortezomib.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Bortezomib.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Bortezomib.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Bortezomib.
UdenafilThe metabolism of Udenafil can be decreased when combined with Bortezomib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bortezomib.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Bortezomib.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Bortezomib.
ValsartanThe metabolism of Bortezomib can be decreased when combined with Valsartan.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Bortezomib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Bortezomib.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Bortezomib.
VemurafenibThe serum concentration of Bortezomib can be increased when it is combined with Vemurafenib.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Bortezomib.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Bortezomib.
VerapamilThe metabolism of Verapamil can be decreased when combined with Bortezomib.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Bortezomib.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Bortezomib.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Bortezomib.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Bortezomib.
VincristineThe metabolism of Vincristine can be decreased when combined with Bortezomib.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Bortezomib.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Bortezomib.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Bortezomib.
Vitamin CThe therapeutic efficacy of Bortezomib can be decreased when used in combination with Vitamin C.
VoriconazoleThe serum concentration of Bortezomib can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Bortezomib.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Bortezomib.
WarfarinThe metabolism of Warfarin can be decreased when combined with Bortezomib.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Bortezomib.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Bortezomib.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Bortezomib.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Bortezomib.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Bortezomib.
ZileutonThe metabolism of Zileuton can be decreased when combined with Bortezomib.
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Bortezomib.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Bortezomib.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Bortezomib.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Bortezomib.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Bortezomib.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Bortezomib.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Bortezomib.
Food Interactions
  • Citrus fruits - Patients should avoid taking extra vitamin C (ascorbic acid) supplements and vitamin C-containing multi-vitamins during their bortezomib therapy. Ascorbic Acid may diminish the therapeutic effect of Bortezomib.
  • Green Tea - Green Tea may diminish the antineoplastic effect of Bortezomib. Avoid concurrent use of green tea extract and other green tea products during treatment with bortezomib.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Threonine-type endopeptidase activity
Specific Function:
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This unit is responsible of the chymotrypsin-like activity of the proteasome and is one of the principal target of the proteasome in...
Gene Name:
PSMB5
Uniprot ID:
P28074
Molecular Weight:
28480.01 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Threonine-type endopeptidase activity
Specific Function:
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity.
Gene Name:
PSMB1
Uniprot ID:
P20618
Molecular Weight:
26489.09 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 03:39